Skip to main content

CORRECTION article

Front. Pharmacol., 18 November 2022
Sec. Neuropharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1075433

Corrigendum: Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders

This article is a correction to:

  1. Striatal Dopamine D2-Muscarinic Acetylcholine M1 Receptor–Receptor Interaction in a Model of Movement Disorders

    1. Read original article
Ren A. J. Crans,René A. J. Crans1,2Elise WoutersElise Wouters1Marta Valle-Len,Marta Valle-León2,3Jaume Taura,Jaume Taura2,3Caio M. Massari,Caio M. Massari2,4Víctor Fernndez-Dueas,Víctor Fernández-Dueñas2,3Christophe P. Stove &#x;Christophe P. Stove1*†Francisco Ciruela, &#x;Francisco Ciruela2,3*†
  • 1Laboratory of Toxicology, Department of Bioanalysis, Ghent University, Ghent, Belgium
  • 2Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL-Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain
  • 3Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain
  • 4Programa de Poìs-graduação em Bioquiìmica, Centro de Ciencias Bioloìgicas, Universidade Federal de Santa Catarina, Florianoìpolis, Brazil

A Corrigendum on
Striatal dopamine D2-muscarinic acetylcholine M1 receptor– receptor interaction in a model of movement disorders

by Crans RAJ, Wouters E, Valle-León M, Taura J, Massari CM, Fernández-Dueñas V, Stove CP and Ciruela F (2020). Front. Pharmacol. 11:194. doi: 10.3389/fphar.2020.00194

In the published article, there was an error in Figure 1A as published. The immunoblot panel corresponding to the Lysates/IB: anti-FLAG (upper left corner) was erroneously swapped with the immunoblot panel of IPs: anti-HA/IB: anti-HA (lower right corner). The corrected Figure 1 and its caption appear below.

FIGURE 1
www.frontiersin.org

FIGURE 1. D2R-M1R interaction in transiently transfected HEK293T cells. (A) Co-immunoprecipitation. HEK293T cells were harvested and lysed 48 h after transfection. The lysates were used for immunoblotting (IB) with anti-FLAG and anti-HA antibodies to demonstrate D2R and M1R expression, respectively (left panels). The rest of the samples (immunoprecipitates; IPs) were subjected to immunoprecipitation with a mouse anti-HA antibody. The CoIP was confirmed via the detection of FLAG-D2R upon IB with rabbit anti-FLAG and rabbit anti-HA antibodies (right panel; boxed lane). Data shown are representative of three independent experiments. (B) BRET1 saturation curve. The BRET1 signal in HEK293T cells co-expressing a constant amount of D2R-Rluc and increasing amounts of M1R-YFP (n = 5) or YFP (n = 3) constructs was measured 48 h post-transfection. The BRET1 saturation curve is derived from all independent experiments. (C) NanoBiT® complementation assay. The SmBiT and LgBiT parts of the NanoLuciferase fragments were fused to the C-terminus of the indicated receptor. The constructs were overexpressed via transient transfection in HEK293T cells. Results are presented as mean ± SD (n = 3). Statistical significance was tested using the nonparametric ANOVA by ranks of Kruskal–Wallis followed by the Dunn’s multiple comparisons post-hoc test, * = p ≤ 0.05.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: D2R, M1R, sumanirole, VU0255035, striatum, Parkinson’s disease

Citation: Crans RAJ, Wouters E, Valle-León M, Taura J, Massari CM, Fernández-Dueñas V, Stove CP and Ciruela F (2022) Corrigendum: Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders. Front. Pharmacol. 13:1075433. doi: 10.3389/fphar.2022.1075433

Received: 20 October 2022; Accepted: 14 November 2022;
Published: 18 November 2022.

Edited and reviewed by:

Luis F. Callado, University of the Basque Country, Spain

Copyright © 2022 Crans, Wouters, Valle-León, Taura, Massari, Fernández-Dueñas, Stove and Ciruela. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Christophe P. Stove, christophe.stove@ugent.be; Francisco Ciruela, fciruela@ub.edu

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.